Elanco Animal Health posted Q3 2026 revenue of $1.265 billion, up 11% year-over-year with 9% organic growth, driven by strong demand for products like Zenrelia and Credelio Quattro. The company raised its full-year 2026 revenue guidance to $5.155-$5.18 billion and adjusted EBITDA guidance to $1.05-$1.065 billion, reflecting margin expansion and improved profitability. Elanco also achieved a net leverage ratio milestone of 2.9x, enhancing capital flexibility, and provided a positive early outlook for 2027 with continued growth expected. This performance highlights Elanco's strong market position and innovation-driven growth in animal health.
Elanco Animal Health's stock is up 6.80% on Pluang, trading at USD 25.28 as investors respond to its strong Q3 results and raised guidance. The stock's market cap stands at $11.83 billion with a 52-week high of $26.84. These figures are as of Nov 06, 2026 18:41 WIB.
A recent survey of over 2,000 U.S. consumers by Elanco Animal Health shows that 93% of pet owners have maintained or increased their spending on pet health in the past three months, despite cost-of-living challenges. The survey highlights that pet he...
On November 6, Moderna, Humana, and Elanco will release earnings reports that could impact their stock rallies. Humana's Medicare Advantage update is crucial for retirees, with a focus on medical costs and membership trends. Elanco faces supply chall...
